GENEVA--(BUSINESS WIRE)--Regulatory News:
Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of June 30, 2017, the following assets appeared on the liquidity account:
- Number of shares: 33,678
- Cash balance of the liquidity account: € 284,643.00
As a reminder, as of December 31, 2016, the following resources were booked to the liquidity account:
- Number of shares: 27,778
- Cash balance of the liquidity account: € 360,165.12
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and Lyon. It has 31 employees and rights to 16 patent families protecting its technology.
For more information, visit: www.geneuro.com
Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com